Search

B Introduction: b Glofitamab (Glofit) is a novel T-cell engaging bispecific antibody. Glofitamab plus immunochemotherapy demonstrates durable efficacy with manageable safety in relapsed/refractory non-Hodgkin lymphoma (R/R NHL): update of a Phase Ib study B Conclusions: b This trial demonstrated that Glofit plus R-CHOP demonstrated high BORR and CMR rates in pts with R/R NHL, with durable responses observed after >=2 years' follow-up. [Extracted from the article]

For pts with 1 prior therapy ( I n i = 10), the CR/CRi rate was 90% (95% CI, 55-100) and for pts with >=2 prior therapies ( I n i = 45), the CR/CRi rate was 67% (95% CI, 51-80); medians (95% CI) for OS were not reached (NR; 2.1-NE) and 25.6 mo (14.2-38.9), respectively. 3-Year outcomes of adults with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexu-cel in ZUMA-3 by age, prior therapies, and subsequent transplant B Background: b Brexucabtagene autoleucel (brexu-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved in the US for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) and in the EU for adults >=26 years with R/R B-ALL based on positive results of ZUMA-3. [Extracted from the article]

B Introduction: b Axicel is approved for treatment of r/r PMBCL beyond the 2nd treatment line (>2L). Axicabtagene ciloleucel (Axicel) for relapsed/refractory primary mediastinal B-cell lymphoma (r/r PMBCL) compared to DLBCL-NOS: A GLA/DRST registry study B Results: b Altogether, 13 patients with PMBCL were identified in the total sample of 173 patients treated with axicel, along with 131 DLBCL patients. [Extracted from the article]

The Cerebral Palsy Register in eastern Denmark has collected cases using a uniform data sampling procedure since birth year 1979. We have investigated changes in the rate of cerebral palsy, related to gestational age, mortality and perinatal risk factors in children born 1983--90. The total cerebral palsy birth prevalence decreased from 3.0 in the birth year period 1983--86 to 2.4 per 1000 live births (P < 0.01) in 1987--90, owing to a decrease among all preterm infants (29--19 per 1000, P < 0.001). The perinatal and early neonatal mortality in preterm infants was unchanged from 1983--86 to 1987--90. The rate of cerebral palsy in term infants was 1.5 per 1000 in all birth-year periods from 1979--90. Among the cerebral palsy infants, the proportion of very preterm babies treated with mechanical ventilation in the neonatal period decreased from 95% in 1983--86 to 61% in 1987--90 (P < 0.001), while the group treated with CPAP among the moderately preterm babies increased from 61% to 78% (P < 0.05). The significant decline in cerebral palsy rate in preterm infants born 1987--90 may be due to a change in treatment at the neonatal intensive care units using less mechanical ventilation, a hypothesis which needs further investigation. [ABSTRACT FROM AUTHOR]

Biomarkers for cytopenias following CAR T-cell treatment in relapsed/refractory (RR) multiple myeloma (MM) are not completely defined. We prospectively analysed 275 sequential peripheral blood (PB) samples from 58 RRMM patients treated with BCMA-targeted CAR T cells, and then divided them into three groups: (i) baseline (before leukapheresis), (ii) ≤day+30, and (iii) >day+30 after CAR T-cell therapy. We evaluated laboratory data and performed flow cytometry to determine the (CAR) T-cell subsets. Baseline hyperferritinaemia was a risk factor for long-lasting grade ≥3 anaemia (r = 0.47, p < 0.001) and thrombocytopenia (r = 0.44, p = 0.002) after CAR T-cell therapy. Low baseline haemoglobin (Hb) and PLT were associated with long-lasting grade ≥3 anaemia (r = -0.56, p < 0.001) and thrombocytopenia (r = -0.44, p = 0.002) respectively. We observed dynamics of CAR-negative T-cell subsets following CAR T-cell infusion. In the late phase after CAR T-cell therapy (>day+30), CD4Tn frequency correlated with anaemia (r = 0.41, p = 0.0014) and lymphocytopenia was related to frequencies of CD8 + T cells (r = 0.72, p < 0.001) and CD8Teff (r = 0.64, p < 0.001). CD4Tcm frequency was correlated with leucocytopenia (r = -0.49, p < 0.001). In summary, preexisting cytopenias and hyperferritinaemia indicated long duration of grade ≥3 post-CAR T-cell cytopenias. Prolonged cytopenia may be related to immune remodelling with a shift in the CAR-negative T-cell subsets following CAR T-cell therapy., (© 2024 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.)